IN VIVO MEMBRANE TOPOLOGY OF ESCHERICHIA COLI SEC A ATPASE REVEALS EXTENSIVE PERIPLASMIC EXPOSURE OF MULTIPLE FUNCTIONALLY-IMPORTANT DOMAINS CLUSTERING ON ONE FACE OF SEC A

Lucia B. Jilaveanu and Donald Oliver
Molecular Biology and Biochemistry Department, Wesleyan University, Middletown, CT 06459

Running Title: SecA Membrane Topology

Address correspondence to: Donald Oliver, Molecular Biology and Biochemistry Department, Wesleyan University, Middletown, CT 06457; Tel. 860-685-3556; Fax. 860-685-2141; E-mail: doliver@wesleyan.edu

The Sec-dependent protein translocation pathway promotes the transport of proteins into or across the bacterial plasma membrane. SecA ATPase has been shown to be a nanomotor that associates with its protein cargo as well as the SecYEG channel complex and to undergo ATP-driven cycles of membrane insertion and retraction that promote stepwise protein translocation. Previous studies have shown that both the 65 kDa N- and 30 kDa C-domains of SecA appear to undergo such membrane cycling. In the present study we have performed in vivo sulfhydryl labeling of an extensive collection of monocysteine secA mutants under topologically specific conditions in order to identify regions of SecA that are accessible to the trans side of the membrane in its membrane-integrated state. Our results show that distinct regions of five out of six SecA domains were labeled under these conditions, and such labeling clusters to a single face of the SecA structure. Our results demarcate an extensive face of SecA that interacts with SecYEG and is in fluid contact with the protein-conducting channel. The observed domain-specific labeling patterns should also provide important constraints on model building efforts in this dynamic system.

The major Sec-dependent protein translocation pathway of Eubacteria, which is essential for both protein secretion and integral membrane protein insertion, has been subjected to intensive investigation for over two decades. Its core components consist of the SecA ATPase nanomotor along with SecYEG, the presumed protein-conducting channel (reviewed by (1,2)). Peripheral components such as the export-specific SecB chaperone, which maintains preproteins in a loosely folded export-competent state and transfers them to SecA, along with the integral membrane SecDF complex, which plays an as yet unknown role in the process, are important for rapid and efficient protein translocation (3-5).

The protein translocation reactions are organized by the SecA ATPase nanomotor, a complex protein that consists of 65 kDa N- and 30 kDa C-domains (6,7). The N-domain consists of two nucleotide-binding domains, NBF-I and NBF-II, which together form a high affinity nucleotide-binding cleft, while a protein substrate-binding domain, PPXD, is attached to NBF-I and is subject to its modulation (8-10). The C-domain consists of a central helical scaffold domain, HSD, an organizing center upon which the various other domains of SecA reside, a helical wing domain, HWD, and a carboxyl-terminal region, CTR, that contains both acidic phospholipid and SecB binding sites (11,12).

Soluble, peripheral membrane, and integral membrane pools of SecA have been described previously (13). Membrane-bound SecA consists of a pool bound via acidic phospholipids as well as one bound with nanomolar affinity to SecYEG, the SecA receptor (14,15). Both free and membrane-bound SecA have the capacity to interact directly with preproteins or to receive them via transfer from the SecB-preprotein complex (14,16,17). By simultaneously binding both protein substrates as well as SecYEG, SecA is able to initiate protein translocation.

The dominant model for Sec-dependent protein translocation posits that a mobile region of SecA undergoes ATP-driven cycles of membrane insertion and retraction at SecYEG in order to promote the stepwise translocation of proteins (referred to as SecA membrane cycling) (18). This model was originally based on the observation that both the N and C-domains of SecA appeared to
undergo membrane insertion in an ATP, preprotein, and SecYEG-dependent fashion based on their protease-resistant state as well as their accessibility to labeling reagents that specifically label only the exterior side of the membrane (6,18-21). SecA has also been shown to undergo a default membrane insertion reaction in the presence of non-hydrolyzable ATP analogs (22). However, the additional observation that the protease-resistant state of the C-domain could also be induced in the presence of micellar SecYEG and a non-hydrolyzable ATP analog and under conditions where SecYEG was degraded to small peptides has led to the alternative suggestion that these translocation ligands simply induce a stable SecA conformational state (23).

The structure of SecYEG protein, its conformational flexibility, and the dimensions and topology of the protein-conducting channel should provide important clues into the molecular basis of SecA membrane cycling. However, these topics have been the source of considerable controversy. Monomeric, dimeric, and tetrameric states for SecYEG have been detected in various biochemical and structural studies, where the presence of SecA, preprotein and ATP stimulated the formation of dimeric and tetrameric forms of SecYEG (see (1,24) and references contained within). A small 5-8 Å protein-conducting channel has been proposed to lie within the SecYEG protomer, while a much larger channel of ~20 Å would be formed at the interface of SecYEG oligomers in the ring-like structures that have been observed previously (25-28). Recent studies favor the former model. In one study utilizing cryo-electron microscopy reconstruction, a ribosome-nascent chain complex was captured associated with a SecYEG dimer, where one protomer formed the active protein-conducting channel, while the second protomer was in an inactive state (29). In a second study utilizing cysteine-scanning mutagenesis and disulfide bond formation, the translocating polypeptide chain was located exclusively within the central region of SecY (30). Such a narrow channel, which begins with a 20-25 Å opening but narrows to 5-8 Å at the pore ring at the middle of the membrane would significantly limit both the depth and extent of SecA membrane insertion at SecYEG.

Clearly a high-resolution structure of SecA in its membrane-inserted state at SecYEG with or without a translocation intermediate is required to elucidate the structural dynamics of the translocon. However given the difficulty in obtaining crystals of dynamic membrane proteins that diffract to atomic dimensions, this approach is likely to be difficult to achieve. The structure of the SecY complex from _M. jannaschii_ that was obtained recently is of limited use, since Archaea do not possess a SecA homolog, but instead utilize the signal-recognition particle-mediated pathway for protein secretion (25,31). Therefore, other approaches to obtain such structural information need to be sought.

Cysteine-scanning mutagenesis combined with either topologically specific sulfhydryl labeling or disulfide bond formation has been shown to be a powerful method to assess membrane protein structure and topology. For example, considerable information on the proximity of the different transmembrane helices and cytosolic or periplasmic domains of SecYEG protein has been obtained utilizing this approach (reviewed by (1)). In addition, _in vivo_ assessment of the periplasmic accessibility of engineered cysteine residues within an integral membrane protein to membrane-impermeable sulfhydryl reagents has been utilized to derive the topology of membrane transporters in a less invasive manner than through the utilization of more conventional _in vitro_ approaches (reviewed by (32)).

Previously we utilized cysteine-scanning mutagenesis along with MPB labeling in RSO to demonstrate that at least three distinct regions within PPXD, NBF-II, and CTR of integral-membrane SecA were periplasmically accessible (20). This approach is limited however by the laboriousness of the methodology as well as potential artifacts induced during spheroplasting and osmotic rupture: a particular concern given the highly dynamic nature of the Sec system. In the present study we have utilized _in vivo_ rather than _in vitro_ topology labeling in order to minimize system perturbation, and we have greatly expanded the number of cysteine mutants that have been examined. Our results provide the first detailed look at the membrane topology of integral
membrane SecA protein in a more physiological manner.

**EXPERIMENTAL PROCEDURES**

*Strains, Plasmids, and Chemicals— E. coli BL21.19 (secA13(Am) supF(Ts) trp(Am) zch::Tn10 recA::CAT clpA::KAN) is derived from BL21(λDE3) (33) and was used as the host for all secA-containing plasmids. Plasmid pT7secA-Cys0, a derivative of pT7secA2 that has all four cysteine codons within secA changed to serine, has been described previously (20); it was used to create the collection of monocysteine secA mutants described here utilizing a Quik-Change site-directed mutagenesis kit (Stratagene) and appropriate oligonucleotides (Integrate DNA Technologies) as described by the manufacturer. All secA mutants were verified by DNA sequence analysis utilizing the DNA sequence facility at University of Pennsylvania. The efficiency of plating of a given secA mutant was obtained by plating an appropriate dilution of an overnight culture of the strain on LB Amp plates and incubating them overnight at either 42°C or 30°C, and it is defined as the ratio of the titer of colonies obtained at 42°C divided by that obtained at 30°C times 100%. MPB and AMS were purchased from Molecular Probes, Inc. Unless otherwise noted, most other chemicals were reagent grade or better and were obtained from Sigma or a comparable supplier.

In vivo MPB labeling of cells—Each monocysteine secA mutant was grown in LB medium supplemented with ampicillin (100 µg/ml) at 42°C to an *A*<sub>600</sub> of 0.65-0.7, when the culture was chilled rapidly on ice for 10-20 min and harvested by sedimentation at 7,000 × g for 10 min at 4°C. The cell pellet was resuspended in 0.075 volumes of buffer 1 (50 mM Hepes, pH 7.6, 250 mM sucrose, 5 mM EDTA). Where specified, the resuspended culture was incubated with 5 mM AMS at 4°C for 90 min followed by sedimentation at 20,000 × g for 10 min at 4°C, when the cell pellet was washed and resuspended in and equivalent volume of buffer 1 prior to MPB labeling. In other experiments the resuspended culture was incubated with 0.1% Triton X-100 at 0°C for 15 min prior to MPB labeling. Biotinylation was performed by incubation with 75 µM MPB for 3 min at 0°C. Labeling was quenched by addition of 2-mercaptoethanol to 500 mM and incubation at 0°C for 5 min followed by sedimentation of cells at 20,000 × g for 10 min at 4°C. The cell pellet was resuspended in an equivalent volume of buffer 2 (50 mM Hepes, pH 7.6, 150 mM NaCl, 5 mM EDTA) supplemented with 200 mM 2-mercaptoethanol. In certain instances the MPB labeling pattern was analyzed directly on total cell protein by addition of sample buffer (2% SDS, 125 mM Tris-HCl, pH 6.8, 5% 2-mercaptoethanol, 15% glycerol, 0.005% bromophenol blue) followed by SDS-PAGE and immunoblotting as described previously (34). In other cases the MPB labeling pattern was analyzed on subcellular fractions. For this purpose cells were broken by two passages at 8,000 lb/in<sup>2</sup> in a French pressure cell, and unbroken cells were removed by sedimentation at 13,000 × g for 10 min at 4°C, giving rise to the total cleared lysate (Total). Soluble (S300) and membrane (P300) fractions were prepared by sedimentation of the total cleared lysate at 320,000 × g for 30 min at 4°C in a Sorvall RC M100 micro-ultracentrifuge. S300 was removed, and P300 was resuspended in one sixth of the original volume of buffer 2. Following addition of sample buffer and SDS-PAGE and immunoblotting, visualization of biotinylated proteins utilized streptavidin-conjugated horseradish peroxidase (Molecular Probes) and ECL (Pierce), while visualization of SecA content employed primary rabbit anti-SecA antisera and secondary goat anti-rabbit IgG-conjugated horseradish peroxidase (Pierce) and ECL.

**RESULTS AND DISCUSSION**

*Construction of Monocysteine secA mutants and In Vivo Labeling with MPB—* Previous studies have demonstrated the feasibility of performing a topological analysis of membrane proteins utilizing a cysteine-scanning approach combined with *in vivo* labeling with sulfhydryl-reactive reagents (reviewed by (32)). In order to undertake a similar approach with SecA ATPase, we created an extensive collection of monocysteine secA mutants. The mutations were targeted according to four principles: (i) we sought a mutation density that would provide us with
detailed topological information on the different SecA domains, resulting in a collection of 63 monocysteine mutants for the 901 amino-acid-residue SecA protein, (ii) by inspection of the homologous B. subtilis SecA structure (8) (the two proteins have 50% identity at the amino acid sequence level (35,36)), we attempted to confine our selection of monocysteine substitutions to either surface-accessible residues or residues that are located at domain-domain interfaces; the latter residues could readily become surface-accessible by a change in SecA conformation during its membrane insertion, (iii) in order to avoid non-functional secA mutants that would be difficult to grow in a haploid state and which could give rise to spurious results, we utilized an alignment of existing Eubacterial SecA protein sequences to avoid highly conserved amino acid residues, and where feasible, we placed the substitution at a site where a naturally occurring cysteine residue was located in one of the SecA homologs, and (iv) we tried to choose amino acid residues that are structurally/chemically similar to cysteine for substitution.

The monocysteine substitutions were made on a plasmid-borne functional copy of the secA gene in which its four naturally occurring cysteine codons were substituted with serine (see “Experimental Procedures”). secA function was assessed in BL21.19, where chromosomal secA expression can be shut off by growth at 42°C because of the presence of a secA amber mutation and a temperature sensitive amber suppressor (37). Nearly all of our monocysteine secA mutants were functional in vivo as assessed by the ability of the appropriate plasmid-borne secA allele to complement the secA amber defect at 42°C, and they gave rise to plating efficiencies of 25% or greater in general (defined in “Experimental Procedures”). The few monocysteine secA mutants that were non-functional were not subjected to further analysis in this study.

In order to label regions of SecA in a topologically specific manner, we grew our strains under conditions where only the monocysteine-containing secA gene copy was expressed at a moderate level (at 42°C and without IPTG induction), and we employed the readily detectable sulfhydrol-labeling reagent, MPB. Previous studies have shown that when MPB is utilized at low concentrations, it is impermeable to the plasma membrane and can be used to map periplasmically-accessible portions of membrane proteins (38,39) also shown below. The topological specificity of MPB labeling of SecA in RSO has also been demonstrated previously (20). In piloting our experiments we found that analysis of membrane fractions of in vivo-labeled strains gave better clarity and sensitivity in our Western blots, although it was possible to directly analyze unfractionated cells as well. These procedures allowed us to directly compare the SecA labeling intensities of our different mutants without the use of immunoprecipitation or affinity purification that complicate comparisons due to the high degree of variability in sample recovery. In addition, we found that by running the SDS-PAGE gels for a longer time, better separation of high molecular weight membrane proteins in the range of SecA was achieved.

By utilizing an MPB concentration and labeling time similar to our previous study we were able to achieve topologically specific labeling of SecA in vivo based on four criteria: (i) Cys530, which has been shown previously to label strongly with MPB in RSO (20), was strongly labeled under our new regimen when the relevant P300 fraction was examined. By contrast, Cys0, which lacked any cysteine residues, was not labeled even though both proteins were present at comparable levels (Fig. 1, compare panels A & B), (ii) Cys530 labeling was prevented by pre-treatment of cells with AMS (Fig. 1A), which has been utilized extensively to demonstrate topologically specific labeling by sulfhydryl-reactive reagents due to its membrane impermeability (39), (iii) Cys530, Cys350, and Cys470, which have been shown previously to label strongly, moderately, and weakly in RSO (20), respectively, gave a similar in vivo labeling pattern, and furthermore, strong labeling was observed in these latter two cases if the integrity of the plasma membrane was breached by Triton X-100 treatment prior to labeling (Fig. 1A), and (iv) only membrane-associated SecA and not soluble SecA was labeled in vivo unless the plasma membrane was permeabilized by Triton X-100 treatment prior to labeling (Fig. 1, compare panels A & C which contain the P300 and S300 fractions, respectively). The single, prominent, MPB-
labeled, soluble protein of unknown identity in S300 fractions was presumably periplasmic in origin and was unrelated to SecA. We note as previous authors have done that there was a relatively small number of MPB-labeled membrane proteins in our P300 (Fig 1A) due to the fact that most naturally occurring cysteine residues that are accessible to the trans side of the membrane often participate in disulfide bond formation (40). This circumstance makes in vivo labeling with sulfhydryl-reactive reagents ideal when combined with a cysteine-scanning mutagenesis approach provided that expression levels of the test membrane protein are sufficient for ready detection.

In order to demonstrate that our procedure labeled SecYEG-bound SecA protein, we investigated the SecYEG-dependence of MBP labeling. For this purpose we compared the MPB labeling efficiency of BL21.19 (pBBsecA-his), which contains secA on a low copy number plasmid (34), with BL21.19 (pBBsecA-his, pET610). Plasmid pET610 overproduces SecYEG protein utilizing the powerful Trc promoter (41). The results of this analysis showed that the specific activity of MPB labeling of SecA increased 2.6 fold by SecYEG overproduction after accounting for a 34% lower SecA level in BL21.19 (pBBsecA-his, pET610) compared to BL21.19 (pBBsecA-his) (supplemental Fig. S1). While the observed increase in specific activity of SecA labeling appears to be lower than the increase in SecYEG overproduction, we have previously shown that only a fraction of overproduced SecYEG protein properly assembles in the membrane where it gives rise to an increase in SecA high affinity binding sites and SecA-dependent translocation ATPase activity (42). However, we cannot rule out that some of the MPB labeled residues of SecA arise from periplasmic exposure of a phospholipid-bound pool of SecA, although such speculation is inconsistent with the extractability of this pool of SecA by reagents that classically remove only peripherally-bound membrane proteins (15). In addition, this latter concern is inconsistent with our data given below.

**Data Analysis**—Analysis of the MPB labeling pattern of 63 monocysteine secA mutants is given in Table 1. In order to insure that our data was consistent, we performed two or more independent experiments (with separate Western blots) for each mutant, and positive and negative controls (Cys530 and Cys0, respectively) were included with each experiment. Given a modest degree of variability in labeling intensity and a continuum in labeling strength between strongly and moderately labeled mutants, we divided the labeling patterns into three groups: moderate to strongly labeled, weakly labeled, and unlabeled (M/S, W, and U, respectively). This scoring system provided a fairer representation of our data and eliminated a potentially more subjective bias. A large proportion (43%) of the SecA monocysteine residues are contained within the M/S group, a similar proportion (46%) are contained within the U group, and the remainder (11%) resides within the W group.

Two different types of controls were done to insure the quality of the entire dataset. First, in order to confirm the topological specificity of labeling of the M/S group of mutants, we compared their labeling pattern in the absence or presence of AMS. Inclusion of AMS prevented MPB labeling of SecA and other proteins in all cases (supplemental Fig. S2). Second, in order to better understand the accessibility properties of the U group of mutants, we compared their labeling pattern in the absence or presence of 0.1% Triton X-100. This experiment indicated that these mutants could be divided into two sub-groups. Cys47, Cys142, Cys190, Cys213, Cys287, Cys295, Cys321, Cys371, Cys376, Cys402, Cys409, Cys498, Cys581, Cys630, Cys696, Cys773, Cys774, Cys809, and Cys827 all showed moderate to strong MBP labeling in the presence of Triton X-100 (supplemental Fig. S3). Since this experiment was performed on total cell protein rather than P300 fractions, it did not distinguish whether soluble or membrane-bound SecA (or both) was labeled in this case. In contrast, Cys8, Cys75, Cys279, Cys307, Cys506, Cys542, Cys673, Cys712, Cys718, and Cys744 all showed weak or no MPB labeling in the presence of Triton X-100. Thus approximately one-third of the U mutant group was inaccessible to MPB labeling in vivo under all conditions tested, presumably due to the burying of the relevant cysteine residue within protein (e.g. SecA or SecYEG) or phospholipid. We note in this regard that a recent study indicated...
that multiple regions of SecA became buried after SecYEG and ATP binding as assessed by acrylamide quenching of single tryptophan SecA mutants (43).

Our results were represented on the highly homologous *B. subtilis* SecA dimer structure (8), although we caution the reader that it is uncertain how SecA structure changes upon SecYEG binding and membrane insertion (23,43,44). It has been reported previously that membrane-bound SecA functions as a dimer (34,45-47), although this result has been disputed in favor of a monomer action model and remains controversial (48,49). The MBP-labeling pattern was highlighted on both SecA protomers, since we were unable to distinguish whether any subunit labeling asymmetry was obtained in our study. We note that M/S labeled residues are distributed throughout all structural domains of SecA with the possible exception of HWD, which contains only one such residue at the junction of the HWD and HSD domains. Most importantly, nearly all M/S labeled residues lay on a single face of the dimer (shown in Fig. 2A) (see below for a discussion of the exceptions and their significance). This result was most easily seen when the SecA protomers were viewed from the side, where the M/S labeled residues clustered to one side of SecA (the left-hand side of Fig. 2B & C). PPXD, NBF-II, and CTR, which “sit” on top of the HSD scaffold, dominated the labeled side of SecA. Such an asymmetric labeling pattern argues strongly for the validity of our methodology and dataset. By contrast, the unlabelled residues were distributed throughout the SecA structure (Fig. 2D & E). This latter result was fully anticipated, since beyond the cytoplasmically-oriented residues of SecA, other regions should be buried by their interaction with SecYEG or the membrane. In addition, localized protein fine structure may sterically block or retard MPB labeling chemistry.

In the front-to-front arrangement of the SecYEG dimer that was observed in the recent structure of the *E. coli* protein-conducting channel bound to a translating ribosome-nascent chain complex (29), the SecYEG dimer was cylindrical with a ~95 Å² diameter and ~45 Å height, and it contained both translocationally-active and inactive protomers. This observed size approximates the dimensions of the MPB-labeled face of the SecA dimer (~100 Å² long and ~80 Å² wide as viewed in Fig. 2A), suggesting that SecA may essentially “cover” the cytosolic face of SecYEG in its bound and inserted state. In addition, the depth of MPB labeling of SecA (~15 Å² to 20 Å²) is suggestive of a more shallow insertion mechanism if no major SecA rearrangements were to occur during this process. Conclusive evidence on this latter point must clearly await better structural analysis of the SecA-SecYEG complex in its various translocation states. It is conceivable that some of our MPB-labeled residues were due to periplasmic exposure of phospholipid-bound SecA protein, although this possibility seems unlikely since lipidic SecA has been described as peripheral in nature based on its dissociation from the membrane during sucrose gradient purification or by treatment with chaotropic reagents like urea (15). Furthermore, SecYEG-bound SecA was found to be shielded from phospholipid acyl chains in a photo-crosslinking study (50), indicating that SecYEG-bound SecA does not appear to possess any sizable phospholipid-associated domain.

The PPXD and NBF-II domains showed considerable labeling bias (9 out of 18 and 9 out of 14 residues tested, respectively were in the M/S group; Table 1), even given some variation in our coverage of SecA with monocysteine substitutions. This result is consistent with the proposed role of PPXD as the preprotein-binding domain of SecA that transfers bound preprotein to SecYEG (51-53). Both the 219-244 and 292-319 regions of SecA, which have been proposed to be critical for signal peptide binding (54,55), contain M/S labeled residues. NBF-II serves a regulatory role in SecA by controlling the ATPase cycle of NBF-I, which in turn controls SecA membrane cycling (22,56-58). Thus SecYEG association by NBF-II and its proximity to the protein-conducting channel are likely to be important for coordination of this regulatory activity and SecA-SecYEG crosstalk. The three residues tested in the CTR domain (Cys833, Cys858, and Cys896) were also found to label, consistent with previous results on the periplasmic accessibility of this region. (20). CTR has been shown previously to be important for both SecB and phospholipid-binding activities of SecA (12,17). Thus this region of SecA may play both an early (SecB binding) as well as late
step (regulating or optimizing a membrane-localized step) in protein translocation. Finally, significant labeling of the ~70 Å° long helix in HSD was observed as well. These regions may play more of a structural role in the correct positioning of SecA on SecYEG protein, given the importance of HSD as an organizing center for SecA’s other domains and associated activities.

Although most regions of NBF-I were distal to the labeled face of SecA and were not labeled, there were two exceptions to this rule: both Cys59 and Cys104 showed good labeling. Cys59 is located within an amino-terminal extension “arm” of NBF-I, which would have to undergo significant conformational movement in order to bring it in proximity to the presumed SecA-SecYEG binding interface. Conformational movement of this region is supported by the occurrence of the secA51(Ts) mutation at residue 43, which results in a thermo-induced membrane “stuck” (inserted) phenotype for SecA protein (13,22,35,58,59). Cys104 is within the Walker A motif of NBF-I that is essential for high affinity ATP binding along with regulating the preprotein binding and release and membrane insertion and retraction cycles of SecA (37,60). One possible explanation for this observed result could be that this SecA region alternates between nucleotide-bound channel-distal and nucleotide-free channel-proximal states. For example, it has been suggested that ATP binding at NBF-I may drive the SecA membrane retraction step (8). Thus in both cases, our study suggests conformational movements within NBF-I that need to be visually “captured” through appropriate structural techniques.

Our data provide support for an intriguing model to explain the mode of action of the two-pore translocon observed recently (29). In this model PPXD and NBF-II would serve to gate the active and inactive channels of the SecYEG dimer, respectively. This suggestion is consistent with the observed extensive MPB-labeling pattern of these two comparably-sized domains of SecA and also with their observed functions as preprotein binding and SecA-SecYEG regulatory domains, respectively (51,52,55-57). In this context PPXD and NBF-II labeling could occur on the same protomer or be divided between different protomers depending on SecA oligomeric state (monomer or dimer) as well as SecYEG dimer orientation (front-to-front or back-to-back (29)).

Summing up, our data demarcate a unique and extensive face of SecA primarily comprised of PPXD, NBF-II, and CTR that associates with SecYEG and is in fluid contact with the trans side of the membrane. The size of this region, although considerable, is not out of line with our current structural understanding of SecYEG protein architecture. For example, given the dimensions of the “closed-state” of the proposed protein-conducting channel of the M. jannaschii SecY complex, a substantial portion of SecA would be needed to “plug” the large, funnel-like cavity, 20-25 Å° in diameter, that lies at the channel entrance (25). Other regions of SecA not within this cavity could still be within fluid contact of it. Furthermore, channel opening could accommodate additional regions of SecA as well as create further sites within fluid contact of the open channel. Our domain-specific and overall results provide ample opportunities to study this complex problem further utilizing a combination of genetic, biochemical, and structural approaches.

REFERENCES


FOOTNOTES

The authors thank John Hunt for help in selecting the sites for cysteine-scanning mutagenesis, Susan Bankowski and Dominik Stoegermayer for construction of the monocysteine secA mutant collection and trial experiments utilizing RSO, and Amy Moffo for excellent technical assistance throughout this study. This work was supported by grant GM42033 from NIGMS.

1The abbreviations used are: AMS, 4-acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid; IPTG, isopropyl-β-D-thiogalactopyranoside; MPB, 3-(N-maleimido-propinyl) biocytin; P300, membrane fraction; RSO, right side-out membrane vesicles; S300, soluble fraction; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
### TABLE I

In vivo MPB labeling of monocysteine secA mutants

<table>
<thead>
<tr>
<th>SecA Cys Residue&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Div Residue&lt;sup&gt;b&lt;/sup&gt;</th>
<th>MPB Labeling&lt;sup&gt;c&lt;/sup&gt;</th>
<th>SecA Cys Residue&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Div Residue&lt;sup&gt;b&lt;/sup&gt;</th>
<th>MPB Labeling&lt;sup&gt;c&lt;/sup&gt;</th>
<th>SecA Cys Residue&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Div Residue&lt;sup&gt;b&lt;/sup&gt;</th>
<th>MPB Labeling&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>C0</td>
<td>NA</td>
<td>U</td>
<td>423</td>
<td>403</td>
<td>M/S</td>
<td>827</td>
<td>776</td>
<td>U</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>U</td>
<td>427</td>
<td>407</td>
<td>M/S</td>
<td>833</td>
<td>782</td>
<td>M/S</td>
</tr>
<tr>
<td>47</td>
<td>45</td>
<td>U</td>
<td>447</td>
<td>427</td>
<td>M/S</td>
<td>858</td>
<td>798</td>
<td>M/S</td>
</tr>
<tr>
<td>59</td>
<td>57</td>
<td>M/S</td>
<td>458&lt;sup&gt;d&lt;/sup&gt;</td>
<td>438</td>
<td>M/S</td>
<td>896</td>
<td>836</td>
<td>M/S</td>
</tr>
<tr>
<td>75</td>
<td>73</td>
<td>U</td>
<td>470</td>
<td>450</td>
<td>W</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>102</td>
<td>M/S</td>
<td>498</td>
<td>478</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>142</td>
<td>140</td>
<td>U</td>
<td>506</td>
<td>486</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>188</td>
<td>U</td>
<td>514</td>
<td>494</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>211</td>
<td>U</td>
<td>518</td>
<td>498</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>223</td>
<td>W</td>
<td>530</td>
<td>NA</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>224</td>
<td>M/S</td>
<td>542</td>
<td>NA</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>233</td>
<td>231</td>
<td>M/S</td>
<td>581</td>
<td>532</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>256</td>
<td>243</td>
<td>M/S</td>
<td>597</td>
<td>548</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>265</td>
<td>252</td>
<td>M/S</td>
<td>600</td>
<td>551</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>279</td>
<td>266</td>
<td>U</td>
<td>630</td>
<td>581</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>287</td>
<td>274</td>
<td>U</td>
<td>640</td>
<td>591</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>292</td>
<td>279</td>
<td>W</td>
<td>641</td>
<td>592</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>295</td>
<td>282</td>
<td>U</td>
<td>656</td>
<td>607</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>NA</td>
<td>M/S</td>
<td>661</td>
<td>612</td>
<td>W</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>307</td>
<td>287</td>
<td>U</td>
<td>673</td>
<td>624</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>321</td>
<td>301</td>
<td>U</td>
<td>696</td>
<td>647</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>334</td>
<td>314</td>
<td>M/S</td>
<td>712</td>
<td>663</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>340</td>
<td>320</td>
<td>M/S</td>
<td>718</td>
<td>671</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>344</td>
<td>324</td>
<td>M/S</td>
<td>734&lt;sup&gt;d&lt;/sup&gt;</td>
<td>687</td>
<td>W</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>350</td>
<td>330</td>
<td>M/S</td>
<td>744</td>
<td>NA</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>363</td>
<td>343</td>
<td>W</td>
<td>753</td>
<td>702</td>
<td>M/S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>371</td>
<td>351</td>
<td>U</td>
<td>773</td>
<td>722</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>376</td>
<td>356</td>
<td>U</td>
<td>774</td>
<td>723</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>402</td>
<td>382</td>
<td>U</td>
<td>787</td>
<td>736</td>
<td>W</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>409</td>
<td>389</td>
<td>U</td>
<td>809</td>
<td>758</td>
<td>U</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>The indicated monocysteine secA mutant was grown, MBP labeled, and analyzed as described in the “Experimental Procedures”.

<sup>b</sup>Indicates the homologous residue of B. subtilis SecA. NA indicates “not applicable”, since certain “insertion” regions of E. coli SecA are not present in B. subtilis SecA. Residues lying within each B. subtilis SecA structural domain were color coded according to the convention of Hunt et al. (8).

<sup>c</sup>The MPB-labeling strength was quantified according to the following nomenclature: M/S, medium to strong labeling, W, weak labeling, U, unlabeled.
BL21.19 (pT7secA-Cys458) and BL21.19 (pT7secA-Cys734) had lower plating efficiencies of 12% and 20%, respectively.

FIGURE LEGENDS

**Fig. 1.** Specificity of *in vivo* MPB labeling methodology. *In vivo* MPB labeling was performed as described in “Experimental Procedures”. *A*, Western blot probed with streptavidin-conjugated horseradish peroxidase. *Lane M*, contains molecular weight markers of 116 kDa and 97.4 kDa. *Lane 1*, 1 µg purified wild-type SecA labeled with 75 µM MPB in buffer 2 at 0°C for 3 min. *Lanes 2-8*, 10 µl P300 of the indicated MPB-labeled strain. Each monocysteine secA mutant is indicated by a “C” followed by the residue number that contains the cysteine substitution. *Lane 2*, BL21.19 (pT7secA-Cys0). *Lanes 3 & 4*, BL21.19 (pT7secA-Cys530) labeled without or with AMS pretreatment, respectively. *Lanes 5 & 6*, BL21.19 (pT7secA-Cys350) labeled in the absence or presence of 0.1% Triton X-100, respectively. *Lanes 7 & 8*, BL21.19 (pT7secA-Cys470) labeled in the absence or presence of 0.1% Triton X-100, respectively. *B*, Similar to *A* except that the Western blot was probed with SecA antisera. *C*, Similar to *A* except that 10 µl S300 of each strain was analyzed in the Western blot that was probed with streptavidin-conjugated horseradish peroxidase. *D*, Similar to *C* except that the Western blot was probed with SecA antisera.

**Fig. 2.** Location of MPB-labeled residues on the *B. subtilis* SecA structure. *A*, Top view of the *B. subtilis* SecA dimer structure (8) utilizing the following domain-specific color code: dark blue, NBF-I; light blue, NBF-II; orange, PPXD; dark green, HSD; light green, HWD; brown, CTR. M/S labeled residues are shown as black spheres. *B & C*, Side view of the *B. subtilis* SecA monomer or dimer, respectively. *D & E*, Similar to *B & C* except that both M/S and U labeled residues are depicted as black and yellow spheres, respectively.
Figure 1

A

MWT (kDa)  
116  
97.4  

M 1 2 3 4 5 6 7 8

1 2 3 4 5 6 7 8

B

C

D

SecA  C0  C550  C550 + AMS  C550  C550 + Triton  C470  C470 + Triton

SecA  C0  C550  C550 + AMS  C550  C550 + Triton  C470  C470 + Triton

SecA  C0  C550  C550 + AMS  C550  C550 + Triton  C470  C470 + Triton

SecA  C0  C550  C550 + AMS  C550  C550 + Triton  C470  C470 + Triton

SecA

1 2 3 4 5 6 7 8

1 2 3 4 5 6 7 8

SecA

1 2 3 4 5 6 7

1 2 3 4 5 6 7
Figure 2
SUPPLEMENTAL FIGURE 1. **SecYEG dependence of in vivo MPB labeling of SecA protein.**

BL21.19(pBBsecA-his) or BL21.19(pBBsecA-his, pET610) was grown in LB medium containing appropriate antibiotics as needed (100 μg/ml spectinomycin, 100 μg/ml ampicillin) at 42°C to an A₆₀₀ of 0.4, when IPTG was added to 0.5 mM, and growth was continued for an addition 1 h. Cell harvesting and MPB labeling were performed as described in “Experimental Procedures”. A, Western Blot probed with strepavidin-conjugated Horseradish peroxidase. Lane M, molecular weight marker of 97.4 kDa. Lanes 1-5, the amount of purified SecA protein labeled with 75 μM MPB as described in “Experimental Procedures” is indicated. Lanes 6 & 7, 30 μl of MPB-labeled total cell protein of the indicated strain. B, Similar to A except that the Western blot was probe with SecA and SecY antisera. “B” or “U” indicate samples that were boiled or not boiled, respectively, in sample buffer prior to analysis by SDS-PAGE. Boiling reduces SecY protein levels due to aggregation and is a useful diagnostic. UN-SCAN-IT (Silk Software) was utilized to quantify the level of SecA protein and the extent of its biotinylation in order to determine the specific activity of MPB labeling of SecA.

SUPPLEMENTAL FIGURE 2. **AMS pretreatment blocks in vivo MPB labeling of SecA monocysteine mutant proteins.** Western Blot probed with strepavidin-conjugated Horseradish peroxidase in which 30 μl of in vivo MPB-labeled total cell protein of the indicated strain was analyzed as described in “Experimental Procedures”. “-” or “+” indicates without or with AMS pretreatment.

SUPPLEMENTAL FIGURE 3. **Effect of Triton X-100 pretreatment on the pattern of in vivo MPB labeling of SecA monocysteine mutant proteins.** Western Blot probed with strepavidin-conjugated Horseradish peroxidase in which 30 μl of in vivo MPB-labeled total cell protein of the indicated strain was analyzed as described in “Experimental Procedures”. “-” or “+” indicates without or with 0.1% Triton X-100 pretreatment.
Supplemental Figure 3
In vivo membrane topology of Escherichia coli SecA ATPase reveals extensive periplasmic exposure of multiple functionally-important domains clustering on one face of SecA
Lucia B. Jilaveanu and Donald B. Oliver

*J. Biol. Chem.* published online December 13, 2006

Access the most updated version of this article at doi: [10.1074/jbc.M610828200](http://doi.org/10.1074/jbc.M610828200)

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/early/2006/12/13/jbc.M610828200.citation.full.html#ref-list-1